A Phase 1 interventional study of ECC4703 F0 formulation and ECC4703 F1 formulation in Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Eccogene. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Eccogene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Fatty Liver with a site in Australia — 7 open to participants now, 7 under way, 4 of them phase 3. Fatty Liver · Australia.
Among the 14 studies in Fatty Liver with a site in Australia, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1, and was the 14th registered.
663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.
Browse Fatty Liver studies →7 of the 14 studies in Fatty Liver with a site in Australia are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, United States, Argentina and 31 more countries
Ages 18+
Boehringer Ingelheim · Sites in Australia, United States, Argentina and 34 more countries
Ages 18+
GlaxoSmithKline · Sites in Australia, United States, Argentina and 16 more countries
Ages 18–70
Hoffmann-La Roche · Sites in Australia, United States, Argentina and 22 more countries
Ages 18–75
Hoffmann-La Roche · Sites in Australia, United States, Argentina and 24 more countries
Ages 18–80
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 60 across 432 interventional studies indexed under Fatty Liver.
Median enrollment 260 across the 12 interventional studies, 60 across the 2 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 10 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
3 of the studies in Fatty Liver with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07334080EccogeneECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants | 2027-04 |
| NCT05945537Inipharm Australia Pty LtdA Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH | 2027-05-31 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Fatty Liver with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, randomized, single-dose, 2-part study designed to evaluate the food effect and relative bioavailability of ECC4703 in healthy adult participants.
Part 1 will include 3 cohorts of 16 participants each, completing 2 single-dose crossover periods to assess food effect on ECC4703 formulations (F1, F2, and F3). Part 2 of the study will enroll approximately 24 participants to compare selected formulations from Part 1 to formulation (F0), using an adaptive design to finalize sequence, treatment periods, and food conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of ECC4703 F1 high-fat or fasted state, followed by ECC4703 F1 fasted or high-fat state, respectively, in subsequent treatment periods
Drug: ECC4703 F1 formulation
Participants will receive a single dose of ECC4703 F2 high-fat or fasted state, followed by ECC4703 F2 fasted or high-fat state, respectively, in subsequent treatment periods
Drug: ECC4703 F2 formulation
Participants will receive a single dose of ECC4703 F3 high-fat or fasted state, followed by ECC4703 F3 fasted or high-fat state, respectively, in subsequent treatment periods
Drug: ECC4703 F3 formulation
Participants will receive a single dose of ECC4703 F0 fasted state, followed by ECC4703 F1, F2 or F3 fasted in subsequent treatment periods
Drug: ECC4703 F0 formulation · Drug: ECC4703 F1 formulation · Drug: ECC4703 F2 formulation · Drug: ECC4703 F3 formulation
A single dose of ECC4703 F0
A single dose of ECC4703 F1
A single dose of ECC4703 F2
A single dose of ECC4703 F3
ECC4703 pharmacokinetic (PK) parameters AUC0-tlast
Area under the Plasma Concentration-Time Curve from Time 0 to the Last Measurable Non-Zero Concentration
Time frame: Up to Day 13
ECC4703 PK parameters AUC0-inf
Area under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity
Time frame: Up to Day 13
ECC4703 PK parameters Cmax
Maximum observed plasma concentration
Time frame: Up to Day 13
ECC4703 PK parameters tmax
Time of the maximum observed plasma concentration
Time frame: Up to Day 13
ECC4703 PK parameters AUC0-t
Area under the plasma concentration-time curve up to the last measurable concentration
Time frame: Up to Day 13
ECC4703 PK parameters AUC0-24
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose
Time frame: Up to Day 13
ECC4703 PK parameters AUCextr
percentage of area under the concentration-time curve that is due to extrapolation from the last measurable concentration to infinity
Time frame: Up to Day 13
ECC4703 PK parameters tlag
lag time (time delay between dosing and first observed plasma concentration)
Time frame: Up to Day 13
ECC4703 PK parameters t1/2
elimination half-life
Time frame: Up to Day 13
ECC4703 PK parameters CL/F
apparent clearance
Time frame: Up to Day 13
Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination
Time frame: Up to Day 18
ECC4703 PK parameters AUC0-t
area under the plasma concentration-time curve up to the last measurable concentration
Time frame: Up to Day 13
ECC4703 PK parameters AUC0-24
Area under the plasma concentration-time curve from time 0 to 24 hours post-dose
Time frame: Up to Day 13
ECC4703 PK parameters AUCextr
percentage of area under the concentration-time curve that is due to extrapolation from the last measurable concentration to infinity
Time frame: Up to Day 13
ECC4703 PK parameters tlag
lag time (time delay between dosing and first observed plasma concentration)
Time frame: Up to Day 13
ECC4703 PK parameters t1/2
elimination half-life
Time frame: Up to Day 13
ECC4703 PK parameters CL/F
apparent clearance
Time frame: Up to Day 13
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.
Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ECC4703
Eccogene